Cesium therapy in cancer patients

These studies were performed under my direction, initiated in April, 1981. Twenty-eight patients were
initially treated with CsCl between April, 1981 to October, 1982. They were subjected to various cancer
therapies, e.g., surgery, radiation and chemotherapy, and were considered terminal cases with general
metastatic disease except for three patients who were not previously treated. Three patients were
comatose at the time of the Cs treatment. Thirteen patients died within less than two weeks of treatment.
Each patient showed a reduction in tumor mass by the Cs treatment.

Of the breast cancer patients, the most impressive effect was seen in a female patient who was comatose
at the beginning of the Cs-treatment and was considered a terminal case. The Cs-therapy, with other
ingredients used, was immediately instituted by the nasogastric route because there was no cooperation
from the patient. The daily CsCl dose given amounted to 30 g, 10 g given three times daily. The patient
was able to leave after five days of treatment. However, the patient's fall on the floor resulted in
complications, i.e., fracture of the neck, and death. The autopsy revealed that the cancer metastasis
had essentially eaten away her hip bone causing this tragic accident. The autopsy performed also showed
the presence of very little cancer tissue.

The next most frequent cancer treated was of unknown primary. Treatment of eight cases showed a death
rate of two within fourteen days of treatment and an additional two deaths within twelve months while four
of the patients are still living. In one case, an autopsy was made in a patient after one week of Cs-treatment
and showed a complete disappearance of the cancer.

There were seven cases of colon cancer patients who were treated with CsCl. Two these patients died
within fourteen days, one of these patients had previous massive chemotherapy, and little time was
available to restore her metabolic condition. The previously existing infiltration of the abdominal wall
disappeared. However, no consent was given for an autopsy.

In one lymphoma case, the patient displayed an unusually large abdomen which was hard and he
weighed approximately 250 pounds. This massively enlarged abdomen began to decline in volume, i.e.,
a loss of approximately 120 pounds of body weight was noted after three months of Cs-therapy. The
spleen which was originally maximally enlarged and reaching into the pelvis was reduced to almost normal
size. The liver position was down to about the level of the umbilicus and was also reduced to normal size in
three months. The patient is still living after three years after his discharge. Unfortunately, there is no
follow-up on this patient and he is being maintained on chemotherapy.

DISCUSSION

The results presented demonstrate the rate of efficacy of CsCl in cancer therapy. The total fifty cancer
cases studied show an impressive 50% survival rate. This confirms the work of Messiha reported in these
proceedings showing that the higher the dose is, the more effective it seems to be.

The autopsy obtained from the patient whose death was attributed to traumatic fracture of the neck
indicated that cancer had been initially further advanced resulting in bone destruction. However, in the
absence of cancer after the massive Cs-therapy, it appears that both dosage (as much as 30 g/day) and
route of drug administration (nasogastric pathway) might have contributed to the patient's rapid recovery.

It should be noted, however, that CsCl dose regimens should not exceed 20 to 40 g due to side effects,
mainly nausea, and diarrhea. The author's personal experience with CsCl after an acute dose of 40 g
CsCl indicates that extensive nausea and paresthesia around the mouth are the major side effects. This
is probably due to K depletion.

The usual dose used in the clinic ranges from two to three grams given by mouth three times daily. At a
latter time, at which time there is no indication of cancer presence, the CsCl dosage will be reduced to a
preventative dose between 0.5 to 1 g a day.

The lymphoma case presented shows that CsCl efficiently reduced massive enlargements of spleen and
liver as well as maximal ascites, causing an abdominal configuration of a tight, hard hemisphere, to almost
normalize after three months of therapy. This period of time was required to eliminate such a massive
volume resulting in the reduction of the body weight noted.